| Literature DB >> 21912615 |
Jianghui Wang1, Emily S W Wong, Jane C Whitley, Jian Li, Jessica M Stringer, Kirsty R Short, Marilyn B Renfree, Katherine Belov, Benjamin G Cocks.
Abstract
BACKGROUND: To overcome the increasing resistance of pathogens to existing antibiotics the 10×'20 Initiative declared the urgent need for a global commitment to develop 10 new antimicrobial drugs by the year 2020. Naturally occurring animal antibiotics are an obvious place to start. The recently sequenced genomes of mammals that are divergent from human and mouse, including the tammar wallaby and the platypus, provide an opportunity to discover novel antimicrobials. Marsupials and monotremes are ideal potential sources of new antimicrobials because they give birth to underdeveloped immunologically naïve young that develop outside the sterile confines of a uterus in harsh pathogen-laden environments. While their adaptive immune system develops innate immune factors produced either by the mother or by the young must play a key role in protecting the immune-compromised young. In this study we focus on the cathelicidins, a key family of antimicrobial peptide genes. PRINCIPAL FINDING: We identified 14 cathelicidin genes in the tammar wallaby genome and 8 in the platypus genome. The tammar genes were expressed in the mammary gland during early lactation before the adaptive immune system of the young develops, as well as in the skin of the pouch young. Both platypus and tammar peptides were effective in killing a broad range of bacterial pathogens. One potent peptide, expressed in the early stages of tammar lactation, effectively killed multidrug-resistant clinical isolates of Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii. CONCLUSIONS AND SIGNIFICANCE: Marsupial and monotreme young are protected by antimicrobial peptides that are potent, broad spectrum and salt resistant. The genomes of our distant relatives may hold the key for the development of novel drugs to combat multidrug-resistant pathogens.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21912615 PMCID: PMC3166071 DOI: 10.1371/journal.pone.0024030
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Phylogenetic tree demonstrating superior diversity of antimicrobial peptides in non-eutherian mammals.
Tammar cathelicidin peptides. WAM1 (a) – KRGFGKKLRKRLKKFRNSIKKRLKNFNVVIPIPLPG from MaeuCath1 (Genbank EF624481.1), WAM2 (b) -KRGLWESLKRKATKLGDDIRNTLRNFKIKFPVPRQG from MaeuCath5 (Genbank EF624484.1), Ancestral WAM (*)- RRGFWKRLRRRLRRFGDRIRNRFRNFREKLPDPFPG. Platypus cathelicidin peptides PAM1 (c) – RTKRRIKLIKNGVKKVKDILKNNNIIILPGSNEK from OranCath1 [23] and PAM2 (d) – RPWAGNGSVHRYTVLSPRLKTQ from OranCath2 [23].
Figure 2Tammar cathelicidin gene expression in the mammary gland throughout lactation and in pouch young skin.
D = Day; PY = pouch young. Cath1 and Cath5 correspond to WAM1 and WAM2, respectively. (a) Tammar cathelicidin gene expression in the mammary gland throughout the 350 days of lactation. (b) Tammar cathelicidin gene expression in male D20–D120 pouch young skin and adult lactating female pouch skin. Female pouch young skin and adult non-lactating pouch skin showed similar expression patterns (not shown). Each age group is represented by three different samples and mammary gland and thymus tissues were used as positive controls (+). No template controls (–) were clean.
Antimicrobial activities of cathelicidin peptides.
| Strains | MIC (µM) | |||||
| WAM1 | WAM2 | Ancestral WAM | LL37 | PAM1 | PAM2 | |
|
| ||||||
|
| 0.47 | 1.46 | 0.41 | 5.57 | 0.75 | 0.87 |
|
| 1.14 | 1.58 | 0.96 | 4.30 | 0.47 | 1.11 |
|
| 0.77 | 1.29 | 2.06 | >56 | 1.89 | 0.73 |
|
| ||||||
|
| 1.50 | 2.14 | 1.56 | 8.62 | 1.96 | 3.37 |
|
| 1.01 | 1.39 | 1.42 | 3.01 | 0.56 | 2.42 |
|
| 0.66 | 0.39 | 0.68 | >55 | 0.73 | 0.83 |
|
| 1.22 | 0.63 | 0.07 | 2.24 | 0.25 | 0.51 |
|
| ||||||
|
| 1.30 | 1.47 | 6.45 | >56 | >20 | 2.50 |
Comparison of WAM1 potency to antibiotics ampicillin, tetracycline and chloramphenicol against E. coli.
| MIC (µM) | Relative potency of WAM1 | |
|
| 5.7 | 12 x |
|
| 4.5 | 10 x |
|
| 12.4 | 26 x |
|
| 0.47 |
Activity of WAM1 against antibiotic-resistant gram-negative clinical isolates.
| Isolate description | MIC (µM) |
|
| 0.95 |
|
| 1.90 |
|
| 0.95 |
|
| 0.47 |
|
| 1.90 |
|
| 0.95 |
|
| 0.95 |
|
| 0.95 |
|
| 0.95 |
|
| 0.95 |
|
| >30.4 |
|
| 0.47 |
|
| 1.90 |
|
| >30.4 |
|
| >30.4 |
|
| 1.90 |
|
| 0.95 |
|
| >15.2 |
|
| 1.90 |
|
| 0.47 |
|
| 1.90 |
|
| 0.95 |
|
| 7.59 |
The 19 antibiotic-resistant isolates are marked with an asterisk and those also resistant to colistin are indicated.
WAM1 activity in the presence of high concentrations of NaCl.
| MIC (µM)0 mM NaCl | MIC (µM)150 mM NaCl | MIC (µM)200 mM NaCl | |
|
| 0.9 | 0.9 | 0.9 |
|
| 1.9 | 1.9 | 3.8 |
|
| 0.5 | 0.9 | 0.9 |
Figure 3Time course of K. pneumoniae killing by WAM1 in broth.
Time marked in minutes. [MIC] = 0.47 µM. Antimicrobial assays were performed as described previously [57].
Figure 4Toxicity of WAM1 on human red blood cells.
Haemolytic activity was determined by treating human red blood cells with different concentrations of WAM1 and haemoglobin release measured by absorbance at 450 nm. Samples were incubated at 37°C for 1 hour. PBS and 1% Tween-20 were used as negative and positive controls, representing 0% and 100% hemolytic activity respectively.
Bacteria identified by 16S rDNA sequencing from the pouch of the tammar wallaby around the time of birth.
| Time of colony isolation | 16S rDNA identification | Percentage match |
| Day(-6) |
| 100% |
| Day(-5) |
| 100% |
| Day(-5) |
| 94% |
| Day(-5) |
| 99% |
| Day(-2) |
| 95% |
| Day(-2) |
| 99% |
| Day(0) |
| 100% |
| Day(0) |
| 100% |
| Day(0) |
| 98% |
| Day(0) |
| 100% |
| Day(0) |
| 95% |
| Day(0) |
| 95% |
| Day(+1) |
| 95% |
| Day(+1) |
| 100% |
| Day(+1) |
| 100% |
The low sequence homology observed in these isolates suggests that they may be a novel bacterial species and/or genus. Day (-6, 5, 2) etc indicates 6, 5 and 2 days before birth; Day(0) is day of birth; Day(+1)is the day after birth.
Primer sequences for cathelicidin sequence expression analysis.
| Cathelicidin | Primer | Primer sequence (5′ to 3′) | Length (bp) |
| 3 | Fw |
| 198 |
| Rv |
| ||
| 1,2,4,5,6,7 | Fw |
| |
| 1 | Rv |
| 413 |
| 2 | Rv |
| 245 |
| 4 | Rv |
| 242 |
| 5 | Fw |
| 190 |
| Rv |
| ||
| 7 | Rv |
| 345 |
| 8 | Fw |
| 126 |
| Rv |
| ||
| GAPDH | Fw |
| 351 |
| Rv |
|